These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 1129119)

  • 1. [Letter: A severe case of postural hypotension. Paradoxical treatment by L-dopa combined with an inhibitor of extracerebral dopa-decarboxylase].
    Boismare F; Boquet J
    Nouv Presse Med; 1975 Feb; 4(8):589. PubMed ID: 1129119
    [No Abstract]   [Full Text] [Related]  

  • 2. [Results after 3 to 5 years of treatment of 219 cases of Parkinson's syndrome treated by L-Dopa and an L-Dopa -decarboxylase inhibitor combination].
    Boudin G; Pepin B; Guillard A; Godlewski S; Fabiani JM; Haguenau M
    Rev Neurol (Paris); 1974; 130(7-8):273-84. PubMed ID: 4217929
    [No Abstract]   [Full Text] [Related]  

  • 3. [An excess of dopamine in postsympathectomy orthostatic hypotension. Treatment with a dopa-decarboxylase inhibitor].
    Lebel M; Kuchel O; Barbeau A; Hamet P; Cuche JL; Nowaczynski W; Boucher R; Genest J
    Union Med Can; 1973 Apr; 102(4):819-25. PubMed ID: 4733011
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of a case of grave orthostatic hypotension (Shy-Drager's syndrome) by an association of L-dopa and mono-amine-oxidase inhibitor (author's transl)].
    Boisson D; Annat G; Aimard G; Pequignot JN; Grivet B; Devic M
    Nouv Presse Med; 1977 Dec; 6(41):3839-41. PubMed ID: 593867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letter: Levodopa and dopadecarboxylase in treatment of postural hypotension.
    Boismare F; Boquet J
    Br Med J; 1975 Mar; 1(5957):573. PubMed ID: 1139159
    [No Abstract]   [Full Text] [Related]  

  • 6. [Improvement with the combination of L-dopa and benserazide of postural dysregulations of the cerebral circulation: preliminary study].
    Boismare F; Boquet J; Lefrançois J; Le Poncin M
    Agressologie; 1977; 18(5):285-6. PubMed ID: 602991
    [No Abstract]   [Full Text] [Related]  

  • 7. [Trial use of L-dopa associated with a dopa-decarboxylase inhibitor in Parkinson's syndrome].
    Carotti A; Tomassetti G; Lucciarini L; Barone G; Mugnai A
    Clin Ter; 1974 Jul; 70(1):9-15. PubMed ID: 4153252
    [No Abstract]   [Full Text] [Related]  

  • 8. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P
    Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract]   [Full Text] [Related]  

  • 9. [Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors].
    Cinca I; Serbănescu A; Tudorache B
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982; 27(4):261-70. PubMed ID: 6222452
    [No Abstract]   [Full Text] [Related]  

  • 10. [Letter: Combination of a dopa decarboxylase inhibitor with 5-hydroxytryptophan therapy].
    Lhermitte F; Degos CF; Marteau R
    Nouv Presse Med; 1975 Jan; 4(1):31. PubMed ID: 1079935
    [No Abstract]   [Full Text] [Related]  

  • 11. [The L-dopa test in Parkinson's disease].
    Esteguy M; Bonnet AM; Kefalos J; Lhermitte F; Agid Y
    Rev Neurol (Paris); 1985; 141(5):413-5. PubMed ID: 4048732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
    Puca FM; Megna GF; Masi G; Specchio LM
    Riv Patol Nerv Ment; 1974 Oct; 95(5):676-84. PubMed ID: 4470268
    [No Abstract]   [Full Text] [Related]  

  • 13. Age-dependent depressor effect of L-dopa in dogs with inhibition of extracerebral dopa decarboxylase.
    Wilke WL
    Pediatr Res; 1983 Nov; 17(11):924-5. PubMed ID: 6359046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
    Admani AK; Verma S; Cordingley GJ; Harris RI
    Pharmatherapeutica; 1985; 4(2):132-40. PubMed ID: 4059292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
    Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
    [No Abstract]   [Full Text] [Related]  

  • 16. Modification of the cardiovascular effects of L-dopa by decarboxylase inhibitors.
    Watanabe AM; Parks LC; Kopin IJ
    J Clin Invest; 1971 Jun; 50(6):1322-8. PubMed ID: 5578236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Variation in the pharmacologic affects of decarboxylase inhibitor in variable doses in man].
    Castaigne P; Rondot P; Taberlet A; Baumann N
    Biomedicine; 1974 Dec; 21(12):486-90. PubMed ID: 4462871
    [No Abstract]   [Full Text] [Related]  

  • 18. [Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone (author's transl)].
    Agid Y; Quinn N; Lhermitte F
    Rev Neurol (Paris); 1981; 137(1):49-51. PubMed ID: 7232966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of dihydroergotamine in the prevention and treatment of orthostatic hypotension syndromes in patients with parkinsonism treated with L-dopa].
    Jubert Gruart J; Balcells Riba M
    Arch Neurobiol (Madr); 1974; 37(4):401-12. PubMed ID: 4433212
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.